Codexis, Inc. (FRA:4QK)

Market Cap	89.70M -73.7%
Revenue (ttm)	45.11M -17.9%
Net Income	-54.51M
EPS	-0.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	81
Open	0.9890
Previous Close	0.9930
Day's Range	0.9660 - 0.9905
52-Week Range	0.9415 - 4.2000
Beta	n/a
RSI	36.00
Earnings Date	Feb 27, 2026

About Codexis

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 188
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4QK

Financial Performance

In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.

Financial numbers in USD